News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Paolo Tarantino: Outcomes and Treatment Patterns for Stage I HER2-Positive Breast Cancer
Paolo Tarantino/X
Jan 31, 2025, 07:27

Paolo Tarantino: Outcomes and Treatment Patterns for Stage I HER2-Positive Breast Cancer

Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared on X:

“Our latest study, led by Ada Waks, now out on ACS Journal Cancer. Among ~13,000 patients with stage I HER2+ BC in SEER, those with tumors <1 cm had excellent survival (5y BCSS rate 97.6%–99.6%) irrespective of chemo receipt, whereas a 4% BCSS benefit with chemo was seen in pT1c.”

Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2‐positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010–2019 – Waks – 2025 – Cancer – Wiley Online Library

Authors: Adrienne G. Waks, Paolo Tarantino, Emily L. Chen, Rachel A. Freedman, Nancy U. Lin, Nabihah Tayob, Carlos T. Vallejo, Julieta Leone, Sara M. Tolaney,  Jose Pablo Leone.

Paolo Tarantino: Outcomes and Treatment Patterns for Stage I HER2-Positive Breast Cancer

ACS Journal Cancer Ada Waks Adrienne G. Waks cancer Carlos T Vallejo Emily L Chen Jose Pablo Leone Julieta Leone Nabihah Tayob Nancy U Lin OncoDaily Oncology Paolo Tarantino Rachel A. Freedman Sara M. Tolaney
Special Coverage
Blog
Jan 31, 2025, 07:27
Paolo Tarantino: Outcomes and Treatment Patterns for Stage I HER2-Positive Breast Cancer
Blog
Jan 31, 2025, 07:23
Giuseppe Curigliano: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer
Blog
Jan 31, 2025, 07:21
Shahrin Ahmed: The key solutions for increasing life-saving cervical cancer screenings
Blog
Jan 31, 2025, 07:20
Elvina Almuradova: Pertuzumab + trastuzumab retreatment to prolong OS in HER2+ metastatic breast cancer
Blog
Jan 31, 2025, 07:17
Catherine Alix-Panabières: Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer
Blog
Jan 31, 2025, 07:14
Emily Drake: Thrilled to be in Toronto at The Hospital for Sick Children for the ACCESS annual meeting
Blog
Jan 31, 2025, 07:12
Julie S. Torode: Celebrating the Winners of the APCA\TCT 2024 Photography Competition
Blog
Jan 31, 2025, 07:10
Peter Pisters: More than 2,500 MD Anderson Cancer Center teammates at Quarterly Leadership Meeting
Blog
Jan 31, 2025, 07:03
Toufic Kachaamy: Exciting Opportunity for Fellows!
Blog
Jan 31, 2025, 06:59
Francesca D. Ciccarelli: A constitutive interferon-high immunophenotype defines response to IO in colorectal cancer
Blog
Jan 31, 2025, 06:57
Svetlana Nikic: Unlocking Access to Innovative Diagnostics in Europe
Blog
Jan 31, 2025, 06:55
Paula Ferrada: I’m starting a new position as Department of Surgery Chair at Inova Fairfax Hospital